Summit Therapeutics (SMMT) Stock
Large biotech company developing new medicines. Here's the price, business snapshot, and what's worth knowing about Summit Therapeutics in November 2026.
Summit Therapeutics Inc (ticker: SMMT) is a biotechnology company focused on developing novel therapeutics. With a market capitalisation of about $13.95 billion, the company attracts attention due to its research-led profile and potential upside from clinical development milestones. Investors should know Summit typically spends heavily on research and development and may have little or no recurring revenue until products reach the market. That creates a binary investment profile: positive clinical trial results or regulatory approvals can materially re-rate the stock, while setbacks can depress the share price. Key considerations include cash runway, partnership or licensing deals, the stage of clinical programmes, and regulatory timelines. Biotech shares can be volatile and speculative; they suit investors who can tolerate high risk and long horizons. This summary is educational, not personalised financial advice — values can rise and fall and outcomes are uncertain.
Summit Therapeutics (SMMT) Stock Forecast
Analyst price target, next 12 months
$29.31
+89.5% vs today's $15.47
Price range over the last 12 months
Close to its 12-month low
Analysts covering Summit Therapeutics have a consensus 12-month target of $29.31, above the current price of $15.47.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Summit Therapeutics' stock with a target price of $29.31, indicating strong potential for growth.
Financial Health
Summit Therapeutics is generating solid cash flow and has a respectable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and regulatory decisions can drive major moves in the share price, though outcomes are uncertain and can be binary.
Growth vs Risk
Potential for material upside if therapies advance, balanced by high cash burn, financing needs and sector volatility.
Partnerships Matter
Collaborations or licensing deals can de‑risk programmes or provide funding, but terms and execution affect value and are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
